Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?

Abstract Classical Hodgkin lymphoma (HL) patients achieve excellent outcomes; therefore, treatment de‐escalation strategies to spare toxicity have been prioritized. In a large randomized trial of early‐stage HL patients, omission of chemotherapeutic agents including bleomycin from the standard ABVD...

Полное описание

Библиографические подробности

Главные авторы:	Jillian R. Gunther, Chelsea C. Pinnix, Gordon R. Glober, Kaitlin M. Christopherson, Penny Fang, Hun Ju Lee, Sairah Ahmed, Raphael E. Steiner, Ranjit Nair, Paolo Strati, Sattva S. Neelapu, Loretta J. Nastoupil, Bouthaina S. Dabaja
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Wiley 2020-07-01
Серии:	eJHaem
Предметы:	chemotherapy Hodgkins lymphoma radiotherapy
Online-ссылка:	https://doi.org/10.1002/jha2.1
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!